Sign In
Buy NTLA
$12.02
+0.0800 (+0.670%)
At Close: Aug 10, 2026
Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026
01:55pm, Thursday, 05'th Feb 2026
Intellia Therapeutics is reinstated as a Buy, driven by two late-stage in-vivo gene therapy programs: lonvo-z and nex-z. Key 2026 catalysts are the MAGNITUDE clinical hold decision for ATTR-CM and Pha
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold
10:45am, Wednesday, 28'th Jan 2026
Intellia jumps over 6% after the FDA lifts the clinical hold on the MAGNITUDE-2 study, clearing a path to resume dosing of nex-z in ATTRv-PN.
Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains?
08:36am, Wednesday, 28'th Jan 2026
Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric
Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder
01:03pm, Tuesday, 27'th Jan 2026
The U.S. Food and Drug Administration (FDA) on Tuesday said it removed the clinical hold on Intellia Therapeutics Inc.‘s (NASDAQ: NTLA) Investigational New Drug application (IND) for the MAGNITUDE-2
The Gene-Editing News That Sent Beleaguered Intellia Therapeutics Stock Up 10%
10:22am, Tuesday, 27'th Jan 2026
Intellia Therapeutics stock surged Tuesday after the FDA aid it would allow the company to restart a gene-editing study.
US FDA lifts clinical hold on Intellia's nerve disease trail
08:13am, Tuesday, 27'th Jan 2026
Intellia Therapeutics said on Tuesday that the U.S. Food and Drug Administration has lifted a clinical hold on one of its gene therapy late-stage trial, allowing the company to resume testing its expe
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:16pm, Wednesday, 14'th Jan 2026
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average
10:31am, Wednesday, 14'th Jan 2026
Intellia Therapeutics, Inc. (NTLA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, NTLA broke through the 200-day moving average, wh
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares
05:00am, Monday, 12'th Jan 2026
The president and CEO of Intellia Therapeutics sold 34,146 directly held shares of the firm on Jan. 5. The sale represented 3.09% of John M.
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
07:30am, Wednesday, 07'th Jan 2026
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Intellia Stock Declines Around 55% in 3 Months: Here's Why
12:01pm, Monday, 05'th Jan 2026
NTLA shares plunge 55% in three months after the FDA placed a clinical hold on Nex-Z, suspending trials and milestone guidance following the death of a patient.
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab
06:26am, Wednesday, 31'st Dec 2025
Cathie Wood's ARK Invest made a series of end-of-year portfolio adjustments on the second final trading day of 2025, tilting further toward biotechnology while
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street
09:30am, Monday, 29'th Dec 2025
A clinical hold and a complex commercial path make Intellia Therapeutics' outlook uncertain. Despite steadily growing revenue, Iovance Biotherapeutics faces nearly insurmountable challenges.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 05'th Dec 2025
CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Geode Capital Management LLC Boosts Holdings in Intellia Therapeutics, Inc. $NTLA
04:00am, Saturday, 29'th Nov 2025
Geode Capital Management LLC lifted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) by 5.1% during the undefined quarter, according to the company in its most recent 13F filing with
